- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer | 178 | GlobeNewswire (Europe) | Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage... ► Artikel lesen | |
| 18.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University | 249 | GlobeNewswire (Europe) | Georgia's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of cancer innovation and discovery nationwide CHICAGO, June 18, 2026 (GLOBE... ► Artikel lesen | |
| 10.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial | 309 | GlobeNewswire (Europe) | Additional data from MAIA's THIO-101 expansion may further support an accelerated approval filing with the FDA Potential breakthrough therapy holds substantial commercial opportunity in a projected... ► Artikel lesen | |
| 04.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial | 214 | GlobeNewswire (Europe) | MAIA's novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE... ► Artikel lesen | |
| 03.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion | 263 | GlobeNewswire (Europe) | Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA FDA-cleared IND updates detail latest efficacy data and enriched manufacturing... ► Artikel lesen | |
| 02.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Open Market Purchases by CEO and Director | 3 | GlobeNewswire (USA) | ||
| 22.05. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| MAIA BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 11.05. | MAIA Biotechnology, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 16.04. | MAIA Biotechnology opens first U.S. site for lung cancer trial | 1 | Investing.com | ||
| 16.04. | MAIA Biotechnology, Inc.: MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer | 276 | GlobeNewswire (Europe) | Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks 50,000 advanced NSCLC... ► Artikel lesen | |
| 16.04. | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.04. | MAIA Biotechnology expects $33M capital raise to fund Phase 3 trial of anticancer therapy | 1 | Seeking Alpha | ||
| 08.04. | MAIA Biotechnology, Inc.: MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy | 224 | GlobeNewswire (Europe) | Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential Statistical assessments point to high probability... ► Artikel lesen | |
| 08.04. | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.04. | MAIA Biotechnology, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 31.03. | MAIA Biotechnology, Inc.: MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer | 425 | GlobeNewswire (Europe) | Potential breakthrough therapeutic targets $50B+ global immunotherapy market1 CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a... ► Artikel lesen | |
| 27.03. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.03. | MAIA Biotechnology, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 04.03. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 112,96 | -1,16 % | Novartis, Gilead Sciences und Co. investieren Milliarden - warum jetzt die nächste Generation der Zelltherapie beginnt | ||
| ABBVIE | 223,30 | -1,59 % | Starkes Studiensignal: Positive Wende für AbbVie: Neues Blockbuster-Medikament vor Zulassung | © Foto: SOPA Images - picture alliance / Sipa USAAbbVie hat eine wichtige Empfehlung der europäischen Arzneimittelbehörde erhalten. Damit rückt eine neue Therapie gegen schweren Haarausfall näher.Der... ► Artikel lesen | |
| ABBOTT LABORATORIES | 82,82 | -1,15 % | Gewinner der Börsengeschichte: Jeder Bauer kennt sie - diese Aktie brachte mehr Rendite als Exxon! | © Foto: OpenAI - DALLE (KI-Bild)Bringen Traktoren mehr Rendite als Öl? Eine Studie zu 29.078 US-Aktien und ihrer Buy-and-Hold-Gesamtrendite zwischen 1925 und 2023 zeigt jedenfalls, dass die Aktie von... ► Artikel lesen | |
| INNOCAN PHARMA | 2,090 | +14,52 % | InnoCan Pharma im Blickpunkt: Warum erfahrene Anleger heute zugreifen - Das sollten Sie jetzt wissen | ||
| SCHOTT PHARMA | 18,700 | +7,10 % | DEUTSCHE BANK RESEARCH stuft Schott Pharma auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Schott Pharma von 16 auf 22 Euro angehoben und die Aktien von "Hold" auf "Buy" hochgestuft. Der Spezialist für Verpackung und... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 82,30 | +0,27 % | What You Need To Know Ahead of Edwards Lifesciences' Earnings Release | ||
| ASSEMBLY BIOSCIENCES | 24,500 | +1,03 % | Assembly Biosciences: Der wichtigste HSV-Moment der Biotech-Geschichte steht bevor | Während sich die Biotech-Welt seit Jahren auf Themen wie Adipositas, neuartige Krebstherapien und künstliche Intelligenz fokussiert, könnte sich im Hintergrund eine der größten unentdeckten Chancen... ► Artikel lesen | |
| PENTIXAPHARM | 2,140 | -6,14 % | Pentixapharm beschließt Kapitalerhöhung über bis zu 20,4 Millionen Euro | Die Pentixapharm Holding AG hat die Anfang Juni angekündigte Bezugsrechts-Kapitalerhöhung nun konkret beschlossen. Ausgegeben werden bis zu 11.020.212 neue Aktien, was der Gesellschaft bei voller Platzierung... ► Artikel lesen | |
| FILANA THERAPEUTICS | 1,080 | -0,74 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q1 2026 Financial Results and Business Update | AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 215,50 | -1,82 % | Is Axsome Therapeutics Stock a Millionaire Maker? Here's What the Numbers Say. | ||
| MEDPACE | 490,40 | +0,64 % | Medpace (MEDP) Ascends While Market Falls: Some Facts to Note | ||
| ZEALAND PHARMA | 39,760 | -1,49 % | Zealand Pharma - Transactions related to share buy-back program (week 27, 2026) | ||
| JAGUAR HEALTH | 2,760 | -1,78 % | Jaguar Health, Inc.: Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure | Company remains sharply focused on its ongoing global development program for crofelemer for rare IF diseasesNear-term milestones for IF program buttressed by continuing groundbreaking results of study... ► Artikel lesen | |
| UCB | 257,90 | -0,62 % | UCB Reports Publication Of Data Demonstrating Positive Impact Of KYGEVVI | BRUSSELS (dpa-AFX) - UCB (UCB.BR) announced the publication of two manuscripts in Brain Communications. One manuscript reports integrated safety and efficacy findings for KYGEVVI, demonstrating... ► Artikel lesen | |
| UNITED THERAPEUTICS | 482,40 | -0,92 % | United Therapeutics Buys Thymmune Therapeutics | WASHINGTON (dpa-AFX) - United Therapeutics Corp. (UTHR) on Thursday announced the acquisition of privately held Thymmune Therapeutics for up to $300 million.The transaction includes $140 million... ► Artikel lesen |
MAIA BIOTECHNOLOGY INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 1,465 Euro und damit +0,34 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAIA BIOTECHNOLOGY INC finden Sie auf Wallstreet Online.